Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A study of the Leukemia Cooperative Group of the EORTC and GIMEMA

European Journal of Cancer

Volumn 35, Issue 10, 1999, Pages 1440-1447

  Keating, S ^a   De Witte, T ^b   Suciu, S ^c   Mandelli, F ^d   Damasio, E ^c   Willemze, R ^a   Morra, E ^e   Amadori, S ^g   Dardenne, M ^h   Vegna, M L ^f   Zittoun, R A ^c  

^a EORTC DATA CENTER   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g S EUGENIO HOSPITAL   (Italy)

^h HÔTEL DIEU   (France)

Author keywords

Acute myeloid leukaemia; Allogeneic bone marrow transplantation; Autologous bone marrow transplantation; Centre effect; Intensive chemotherapy; Randomised clinical trials

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CANCER CARE FACILITIES; CHILD; CLINICAL PROTOCOLS; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032867344     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00148-3     Document Type: Article

References (8)

1. Burnett AK, Goldstone AH, Stevens RMF, et cd. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC 10 trial. Lancet 1998, 351, 700-708.
2. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997,90, 2978-2986.
3. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87, 1710-1717.
4. Reiffers J, Stoppa AM, Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukaemia in first remission: the BGMT 87 study. Leukemia 1996, 10, 1874-1882.
5. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995,332, 217-223.
6. Mayer RJ, Davis RB, Schiffer ÇA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994, 331, 896-903.
7. Buyse ME, Staquet MJ, Sylvester RJ. Cancer Clinical Trials; Methods and Practice. Oxford, Oxford Medical Publications, 1992.
8. Shipp M, Niedzwiecki D, Johnson J, et al. High dose CHOP induction therapy for poor prognosis aggressive NHL (CALGB 935 1): FFP differs at high and low accrual institutions. Blood 1998, 92(Suppl. 1), 486a.